This information is intended for use by health professionals

1. Name of the medicinal product

Stelazine 1mg/5ml Syrup

Trifluoperazine 1mg/5ml Syrup

2. Qualitative and quantitative composition

Each 5 ml dose contains 1 mg trifluoperazine present as the hydrochloride.

3. Pharmaceutical form

A clear, pale yellow, peach flavoured syrup.

4. Clinical particulars
4.1 Therapeutic indications

Low dosage: 'Stelazine' is indicated as an adjunct in the short-term management of anxiety states, depressive symptoms secondary to anxiety and agitation. Orally it is also indicated in the symptomatic treatment of nausea and vomiting.

High dosage: 'Stelazine' is intended for the treatment of symptoms and prevention of relapse in schizophrenia and in other psychoses, especially of the paranoid type, but not in depressive psychoses. It may also be used as an adjunct in short-term management of severe psychomotor agitation and of dangerously impulsive behaviour in, for example, mental subnormality.

4.2 Posology and method of administration

Posology

Adults:

Low dosage: 2-4 mg a day given in divided doses, according to the severity of the patient's condition. If necessary, dosage may be increased to 6 mg a day, but above this level extrapyramidal symptoms are more likely to occur in some patients.

High dosage: The recommended starting dosage for physically fit adults is 5 mg twice a day after a week this may be increased to 15 mg a day. If necessary, further increases of 5 mg may be made at three-day intervals, but not more often. When satisfactory control has been achieved, dosage should be reduced gradually until an effective maintenance level has been established.

As with all major tranquillisers, clinical improvement may not be evident for several weeks after starting treatment, and there may be delay before recurrence of symptoms after stopping treatment. Gradual withdrawal from high dosage treatment is advisable.

Paediatric population

Low dosage: For children 3-5 years, up to 1 mg a day given in divided doses.

For children aged 6-12 years, the dosage may be increased to a maximum of 4 mg a day.

High dosage: For children aged under 12 years, the initial oral dosage should not exceed 5 mg a day, given in divided doses. Any subsequent increase should be made with caution, at intervals of not less than three days, and taking into account age, body weight and severity of symptoms.

Elderly

Reduce starting dose in elderly or frail patients by at least half.

Method of Administration:

Oral.

4.3 Contraindications

• Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

• Do not use 'Stelazine' in comatose patients, particularly if associated with other central nervous system depressants.

• Do not use 'Stelazine' in those with existing blood dyscrasias, or known liver damage.

• Patients with uncontrolled cardiac decompensation should not be given 'Stelazine'.

4.4 Special warnings and precautions for use

'Stelazine' should be discontinued at the first sign of clinical symptoms of tardive dyskinesia and Neuroleptic Malignant Syndrome.

Patients on long-term phenothiazine therapy require regular and careful surveillance with particular attention to tardive dyskinesia and possible eye changes, blood dyscrasias, liver dysfunction and myocardial conduction defects, particularly if other concurrently administered drugs have potential effects in these systems.

Care should be taken when treating elderly patients, and initial dosage should be reduced. Such patients can be especially sensitive, particularly to extrapyramidal and hypotensive effects. Patients with cardiovascular disease including arrhythmias should also be treated with caution. Because 'Stelazine' may increase activity, care should be taken in patients with angina pectoris.

If an increase in pain is noted, the drug should be discontinued. Patients who have demonstrated bone marrow suppression or jaundice with a phenothiazine should not be re-exposed to 'Stelazine (or any trifluoperazine) unless in the judgement of the physician the potential benefits of treatment outweigh the possible hazard.

In patients with Parkinson's disease, symptoms may be worsened, and the effects of levodopa reversed. Since phenothiazines may lower the convulsive threshold, patients with epilepsy should be treated with caution, and metrizamide avoided. Although 'Stelazine' has minimal anticholinergic activity, this should be borne in mind when treating patients with narrow angle glaucoma, myasthenia gravis or prostatic hypertrophy. Nausea and vomiting as a sign of organic disease may be masked by the anti-emetic action of 'Stelazine'.

An approximately 3-fold increased risk of cerebrovascular adverse events have been seen in randomised placebo controlled clinical trials in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. Stelazine should be used with caution in patients with risk factors for stroke.

Caution should be used in patients with cardiovascular disease or family history of QT prolongation. Concomitant use of neuroleptics should be avoided.

Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Stelazine and preventive measures undertaken

Acute withdrawal symptoms, including nausea, vomitting, sweating, and insomnia have been described after abrupt cessation of antipsychotic drugs.

Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported. Therefore, gradual withdrawl is advisable.

Phenothiazines should be used with care in extremes of temperature since they may affect body temperature control.

Increased Mortality in Elderly people with Dementia

Data from two large observational studies showed that elderly people with dementia who are treated with antipsychotics are at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known.

Stelazine is not licensed for the treatment of dementia-related behavioural disturbances.

4.5 Interaction with other medicinal products and other forms of interaction

Potentiation may occur if antipsychotic drugs are combined with CNS depressants such as alcohol, hypnotics, anaesthetics and strong analgesics, or with antihypertensives or other drugs with hypotensive activity, anticholinergics or antidepressants. Phenothiazines may antagonise the action of guanethidine and levodopa. Trifluoperazine may aggravate Parkinsonism and antagonise the action of levodopa. They may lower the convulsive threshold. Hence patients with epilepsy should be treated with caution.

Serum levels of phenothiazine can be reduced to non-therapeutic concentrations by concurrent administration of lithium. Dosage increases may be needed.

Desferrioxamine should not be used in combination with 'Stelazine', since prolonged unconsciousness has occurred after combination with the related prochlorperazine.

Trifluoperazine may diminish the effect of oral anticoagulants.

Severe extrapyramidal side-effects or neurotoxicity have been observed in patients concurrently treated with lithium and trifluoperazine. Sleep walking has been described in some patients taking phenothiazines and lithium.

Antacids can reduce the absorption of phenothiazines.

Patients on long-term phenothiazine therapy require regular and careful surveillance with particular attention to tardive dyskinesia and possible eye changes, blood dyscrasias, liver dysfunction and myocardial conduction defects, particularly if other concurrently administered drugs have potential effects in these systems.

Phenothiazines increase the risk of ventricular arrhythmias when given with drugs which prolong the Q-T interval; drugs causing electrolyte imbalances.

4.6 Pregnancy and lactation

Pregnancy

'Stelazine' has been available since 1958. There are some animal studies that indicate a teratogenic effect, but results are conflicting. There is no clinical evidence (including follow-up surveys in over 800 women who had taken low-dosage 'Stelazine' during pregnancy) to indicate that trifluoperazine has a teratogenic effect in man. Nevertheless, drug treatment should be avoided in pregnancy unless essential, especially during the first trimester.

Neonates exposed to antipsychotics (including Trifluoperazine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.

Breast-feeding

Trifluoperazine crosses the placenta and passes into the milk of lactating dogs; breast feeding should only be allowed at the discretion of the physician.

4.7 Effects on ability to drive and use machines

Stelazine may cause side effects including drowsiness, dizziness and visual disturbances which interfere with the ability to drive and operate machinery.

Do not drive or use machines when you first start to take this medicine until you are certain that you are not getting these side effects.

4.8 Undesirable effects

The following undesirable effects may occur with the use of Trifluoperazine in the following frequencies:

Rare (≥1/10,000 to <1/1,000);

Very rare (<1/10,000)

Not known (cannot be estimated from the available data).

The following effects have been reported and are listed below by body system:

System organ class

Frequency

Undesirable effects

Blood and lymphatic system disorders

Very rare

Blood dyscrasias6 such as agranulocytosis, pancytopenia, leucopenia and thrombocytopenia

Endocrine disorders

Not known

Hyperprolactinaemia1, galactorrhoea1, amenorrhoea1, gynaecomastia1

Metabolism and nutrition disorders

Not known

Anorexia, weight gain

Psychiatric disorders

Not known

Unpleasant symptoms2, Confusion,

Nervous system disorders

Rare

Not known

Extrapyramidal symptoms3, Neuroleptic malignant syndrome4,

Tardive dyskinesia5, drowsiness, dizziness, transient restlessness, insomnia,

Eye disorders

Very rare

Not known

Retinopathy, lenticular opacities

Blurred vision

Cardiac disorders

Very rare

Rare

Tachycardia

Serious arrhythmias, sudden unexplained death, cardiac arrest Torsades de pointes

Vascular disorders

Not known

Mild postural hypotension, venous thromboembolism, pulmonary embolism, deep vein thrombosis

Gastrointestinal disorders

Rare

Not known

Very rare

Extrapyramidal symptoms

Dry mouth

Constipation

Hepatobiliary disorders

Very rare

Cholestatic jaundice

Skin and subcutaneous tissue disorders

Not known

Very rare

Photosensitivity reactions,

Skin pigmentation

Musculoskeletal and connective tissue disorders

Not known

Muscular weakness

Renal and urinary disorders

Very rare

Urinary hesitancy and retention

Pregnancy, puerperium and perinatal conditions

Not known

Drug withdrawal syndrome neonatal

General disorders and administration site conditions

Not known

Very rare

Lassitude, oedema, Withdrawal reactions

Hyperpyrexia

Investigations

Rare

ECG changes with prolongation of the QT interval and T-wave changes

Adverse reactions tend to be dose-related and to disappear.

1Hyperprolactinaemia may occur at higher dosages with associated effects such as galactorrhoea, amenorrhoea or gynaecomastia; certain hormone-dependent breast neoplasms may be affected.

2Trifluoperazine even at low dosage may cause unpleasant symptoms of being dulled or, paradoxically, of being agitated.

3Extrapyramidal symptoms are rare at daily oral dosages of 6 mg or less; they are considerably more common at higher dosage levels. These symptoms include parkinsonism; akathisia, with motor restlessness and difficulty in sitting still; and acute dystonia or dyskinesia, which may occur early in treatment and may present with torticollis, facial grimacing, trismus, tongue protrusion and abnormal eye movements including oculogyric crises. These effects are likely to be particularly severe in children. Such reactions may often be controlled by reducing the dosage or by stopping medication. In more severe dystonic reactions, an anticholinergic antiparkinsonism drug should be given.

4The neuroleptic malignant syndrome is a rare but occasionally fatal complication of treatment with various neuroleptic drugs, and is characterised by hyperpyrexia, muscle rigidity, altered consciousness and autonomic instability. Intensive symptomatic treatment, following discontinuation of 'Trifluoperazine', should include cooling. Intravenous dantrolene has been suggested for muscle rigidity.

5Tardive dyskinesia of the facial muscles, sometimes with involuntary movements of the extremities, has occurred in some patients on long-term high dosage and, more rarely, low dosage phenothiazine therapy, including 'Stelazine'. Symptoms may appear for the first time either during or after a course of treatment; they may become worse when treatment is stopped. The symptoms may persist for many months or even years, and while they gradually disappear in some patients, they appear to be permanent in others. Patients have most commonly been elderly, female, or with organic brain damage. Particular caution should be observed in treating such patients. Periodic gradual reduction of dosage to reveal persisting dyskinesia has been suggested, so that treatment may be stopped if necessary. Anticholinergic antiparkinsonism agents may aggravate the condition. Since the occurrence of tardive dyskinesia may be related to length of treatment and total cumulative dosage, 'Stelazine' should be given for as short a time and at as low a dosage as possible.

6Signs of persistent infection should be investigated.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

4.9 Overdose

Symptoms

Signs and symptoms will be predominantly extrapyramidal; hypotension may occur.

Management

Treatment consists of gastric lavage together with supportive and symptomatic measures. Do not induce vomiting. Extrapyramidal symptoms may be treated with an anticholinergic antiparkinsonism drug. Treat hypotension with fluid replacement; if severe or persistent, noradrenaline may be considered. Adrenaline is contraindicated.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Phenothiazine antipsychotics

ATC Code: N05AB06

'Stelazine' is a piperazine phenothiazine tranquilliser with potent antipsychotic, anxiolytic, and anti-emetic activity, and a pharmacological profile of moderate sedative and hypotensive properties, and fairly pronounced tendency to cause extrapyramidal reactions.

5.2 Pharmacokinetic properties

Absorption and Metabolism

Trifluoperazine is well absorbed but undergoes extensive first pass metabolism.

Distribution and Elimination

Distribution is wide and elimination occurs in the bile and urine.

5.3 Preclinical safety data

Not applicable.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium Saccharin

Sodium benzoate

Citric acid, anhydrous

Sodium Citrate

Sorbitol solution

Quinoline Yellow (E104)

Sunset Yellow (E110)

Peach Flavour 85502

Demineralised Water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

'Stelazine' Syrup has a shelf-life of 12 months.

6.4 Special precautions for storage

Store syrup in carton, below 25°C and protect from light. If it is necessary to dilute the syrup use sorbitol solution BP. The diluted syrup is stable for 4 weeks. Store diluted syrup in the dark.

6.5 Nature and contents of container

Amber glass bottle, containing 200 ml of syrup.

6.6 Special precautions for disposal and other handling

None.

7. Marketing authorisation holder

Mercury Pharmaceuticals Ltd,

Capital House,

85 King William Street,

London EC4N 7BL, UK

8. Marketing authorisation number(s)

PL 12762/0029

9. Date of first authorisation/renewal of the authorisation

01/08/98

10. Date of revision of the text

23/03/2020